Liver-on-a-chip, the ideal test environment for CRISPR

Two Arizona State University professors are among the first recipients of Somatic Cell Genome Editing (SCGE) grants from the National Institutes of Health Common Fund. The $2,600,000, five-year grant will fund the first study of the genome editing technology CRISPR to be used on a “human liver-on-a-chip” platform.

Photo
Samira Kiani and Mo Ebrahimkhani, assistant professors in the School of Biological and Health Systems Engineering at Arizona State University, will conduct first study of the genome editing technology CRISPR on a "human liver on-a-chip" platform.
Source: Marco-Alexis Chaira

The SCGE program, launched in January 2018, is aimed at improving therapeutic options for both rare and common diseases, including supporting methods to improve editing the human genome.

Samira Kiani and Mo Ebrahimkhani, assistant professors in the School of Biological and Health Systems Engineering, are combining their expertise in Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR, technology and human microphysiological systems to assess the safety and efficacy of genome editing and its effects on human tissue function.

CRISPR enables researchers to target genes and genetic materials in cells to regulate how they behave and function. Because of CRISPR‘s ease of engineering and programmability, it is considered a breakthrough technology with the potential to help cure disease, repair damaged body tissue and in other ways restore people’s health.

Possible side-effects

However, as with any new technology, applying the CRISPR method can potentially produce some unintended results. “[CRISPR] is a pathogenic source, so to put this in humans, you face a number of concerns, such as toxicity, an immune response, or some other side effects that it might affect cell tissues in humans,” says Kiani, the project lead for the multi-institution endeavor. “There’s a chance introducing the system creates some sort of off-target effects in the genome, meaning that it not only influences the target DNA code, but also does some unintended modifications in parts of the genome that we don’t know [about] and don’t want.”

Kiani and Ebrahimkhani will apply the CRISPR method on the Liverchip® platform in an effort to identify the biomarkers within the human liver genome that indicate toxicity. DNA analysis will also reveal biomarkers that indicate the off-target effects of Cas9 – the DNA-cleaving enzyme used in CRISPR that enables highly precise gene editing and regulation.

Until now, CRISPR has only been tested in animal models or human cell lines. Using the Liverchip® platform provides a model that recapitulates closely human biology and will significantly reduce the number of discrepancies introduced by animal models.

These organ-on-a-chip mediums are essentially a 3D cell culture system designed to have the specific features that would exist in a human body. Multiple cells within the medium self-assemble to generate a tissue similar to a human organ, even mimicking the human body’s blood flow and the profusion of the media in cells. “The final objective is to create a culture system that can predict the liver tissue response in humans,” says Ebrahimkhani, who worked with this platform during his studies at Massachusetts Institute of Technology. “In the long term, we hope to be able to achieve a candidate CRISPR system that can target a specific gene in humans with control over cell type, time of action and any potential toxicity.”

The liver is likely to be one of the first human organs where gene therapies will be tested. Given the frequency of degenerative, genetic diseases associated with metabolism and the function of the liver, using the liver-on-a-chip platform as a proxy for human liver cells is ideal for studying CRISPR/Cas9’s effectiveness as a therapeutic tool.

Subscribe to our newsletter

Related articles

CRISPRoff offers unrivaled control of epigenetic inheritance

CRISPRoff offers unrivaled control of epigenetic inheritance

Scientists have figured out how to modify CRISPR’s basic architecture to extend its reach beyond the genome and into what’s known as the epigenome.

Genome-editing tool TALEN outperforms CRISPR-Cas9

Genome-editing tool TALEN outperforms CRISPR-Cas9

Experiments revealed that TALEN is up to five times more efficient than CRISPR-Cas9 in parts of the genome that are densely packed.

CRISPR to cure sickle cell disease

CRISPR to cure sickle cell disease

University of Illinois Chicago is one of the U.S. sites participating in clinical trials to cure severe red blood congenital diseases such as sickle cell anemia or Thalassemia by safely modifying the DNA of patients’ blood cells.

Using CRISPR to knock down gene messages

Using CRISPR to knock down gene messages

Researchers have harnessed CRISPR technology to target gene messages (messenger RNA) involved in early vertebrate

Using CRISPR to detect diseases

Using CRISPR to detect diseases

Researchers present sensor prototype that can rapidly, precisely, and cost-effectively measure molecular signals for cancer.

Revolutionising CRISPR-Cas

Revolutionising CRISPR-Cas

Researchers have refined the famous CRISPR-Cas method. Now, for the very first time, it is possible to modify dozens, if not hundreds, of genes in a cell simultaneously.

CRISPR-powered device detects genetic mutations in minutes

CRISPR-powered device detects genetic mutations in minutes

Engineers have combined CRISPR with electronic transistors made from graphene to create a new hand-held device that can detect specific genetic mutations in a matter of minutes.

CasX, the smaller CRISPR gene editor

CasX, the smaller CRISPR gene editor

Scientists find new and smaller gene editor: the new gene-editing protein, CasX, may give CRISPR-Cas9 a run for its money.

CRISPR repurposed to develop better antibiotics

CRISPR repurposed to develop better antibiotics

Researchers have repurposed the gene-editing tool CRISPR to study which genes are targeted by particular antibiotics, providing clues on how to improve existing antibiotics or develop new ones.

Popular articles

Subscribe to Newsletter